4.7 Article

CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction

Journal

JOURNAL OF PATHOLOGY
Volume 226, Issue 3, Pages 482-494

Publisher

WILEY
DOI: 10.1002/path.2998

Keywords

CERT; autophagy; LAMP2; HER2; polyploidy; drug resistance

Funding

  1. National Institute of Health [NCI SPORE P50 CA 89393, R21LM008823-01A1]
  2. Danish Council for Independent Research/Medical Sciences (FSS)
  3. Breast Cancer Research Foundation (BCRF)
  4. Medical Research Council
  5. CR-UK
  6. MRC [G0701935] Funding Source: UKRI
  7. Cancer Research UK [15680] Funding Source: researchfish
  8. Medical Research Council [G0701935] Funding Source: researchfish

Ask authors/readers for more resources

Chromosomal instability (CIN) has been implicated in multidrug resistance and the silencing of the ceramide transporter, CERT, promotes sensitization to diverse cytotoxics. An improved understanding of mechanisms governing multidrug sensitization might provide insight into pathways contributing to the death of CIN cancer cells. Using an integrative functional genomics approach, we find that CERT-specific multidrug sensitization is associated with enhanced autophagosomelysosome flux, resulting from the expression of LAMP2 following CERT silencing in colorectal and HER2+ breast cancer cell lines. Live cell microscopy analysis revealed that CERT depletion induces LAMP2-dependent death of polyploid cells following exit from mitosis in the presence of paclitaxel. We find that CERT is relatively over-expressed in HER2+ breast cancer and CERT protein expression acts as an independent prognostic variable and predictor of outcome in adjuvant chemotherapy-treated patients with primary breast cancer. These data suggest that the induction of LAMP2-dependent autophagic flux through CERT targeting may provide a rational approach to enhance multidrug sensitization and potentiate the death of polyploid cells following paclitaxel exposure to limit the acquisition of CIN and intra-tumour heterogeneity. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available